Furthermore, we observed a reduction in the proportion of DLBCL, defined as the percentage of SSC low CD45+ single cells, recovered from rituximab-treated 1 mg/ml collagen spheroids as compared to their control-treated counterparts (Figure 8C). Here, PTPRC is linked to diffuse large B-cell lymphoma.